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Abstract: Alzheimer’s Disease (AD) is a degenerative brain disease caused by cell damage
leading to brain changes such as amyloid plaques and neurofibrillary tangles. Alois Alzheimer
was a clinical psychiatrist and neuroanatomist in Germany who first discovered Alzheimer’s
Disease through microscopic viewing of Auguste D’s brain. Through more research following
Dr. Alzheimer’s death, they began to stage AD. The six stages are: pre-clinical, mild, moderate,
moderately severe, severe, and very severe. The current treatments approved by the FDA work to
slow the progression of AD, rather than modify the disease. There are currently three DiseaseModifying Biologic clinical-trial drugs on the market for AD: Gantenerumab, Lecanemab, and
Solanezumab, each with completed phase one and phase two trials and several phase three trials
in progress.
One Sentence Summary: The research for a cure for Alzheimer’s Disease is escalating, and
disease-modifying biologic drugs are slowly making their way into clinical trials.
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The purpose of this review paper is to give an overview, history, and the phase-three
disease-modifying biologic treatments in clinical trials (gantenerumab, lecanemab, and
solanezumab) for Alzheimer’s Disease (AD). Globally, finding a cure for Alzheimer’s Disease is
5

continuously progressing. Although there are many medications on the market for Alzheimer’s
Disease, none have cured the disease, but rather, slowed down its progression. In the United
States of America, Alzheimer’s Disease is the fifth leading cause of death for those individuals
over the age of 65 years old and the overall seventh leading cause of death in the United States
behind heart disease, cancer, COVID-19, accidents, stroke, and chronic lower respiratory
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diseases (1, 2). AD currently affects more than six million citizens, and in 2050, it is estimated to
affect approximately 13 million (1). Additionally, one in three seniors perishes from Alzheimer’s
Disease or other forms of dementia (1). These statistics bring to light the importance of finding a
cure for AD.
According to the Alzheimer’s Association, dementia is a “general term for loss of
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memory, language, problem-solving and other thinking abilities that are severe enough to
interfere with daily life” (3). Diseases that fall under the term dementia include Alzheimer’s
Disease (60-80%), Lewy Body Dementia (5-10%), Vascular Dementia (5-10%), Frontotemporal
Dementia (5-10%), Parkinson’s Disease, Huntington’s Disease, and Mixed Dementia (3).

2

Alzheimer’s Disease
According to the Alzheimer’s Association,
AD is defined as a degenerative brain disease
caused by cell damage leading to brain changes
5

(4). Physiologically, the brain transforms by
forming amyloid plaques, which are misfolded
protein (amyloid-𝛽𝛽) aggregates present in nerve
junctions, preventing connections between nerve

Fig. 1 Conformations of Amyloid-𝛽𝛽 in Alzheimer's Disease (9)

cells (5,6). Amyloid-𝛽𝛽 has several conformations
10

in the brain when these plaques are overproduced, or clearance is inhibited (7). These may
include soluble monomers, oligomers, protofibrils, insoluble fibrils, and plaque as seen in Fig. 1
(8).
In addition to Amyloid-𝛽𝛽 plaques, fibrillary tangles are
formed as seen in Fig. 2 (6). Hyperphosphorylated tau, encoded

15

by MAPT is the protein that functions to form the core of the
Amyloid-𝛽𝛽 plaques and fibrillary tangles (6). MAPT is located on
chromosome 17 and functions to assemble and stabilize
microtubules in the cell (11). Microtubules work to maintain cell
shape, assist in cell division, and transport materials within cells
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Fig. 2 Amyloid-β plaques and neurofibrillary
tangles (10)

(11). In those individuals with AD, tau will detach from the
microtubules and stick together, consequently forming threads and tangles of tau within neurons
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(12). The drawback of these tangles is that they block the transport system of the neuron,
therefore impairing the synaptic communication between neurons (12).
Initially, these alterations such as amyloid plaques and
fibrillary tangles begin in the entorhinal cortex and hippocampus
5

of the brain, which affects the individual’s memory (5). The
locations of these areas of the brain can be seen in Fig. 3. The
entorhinal cortex functions as a mediator for information that is
entering and leaving the hippocampus, where the processes of
learning and memory occur (13). Furthermore, other areas of the
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Fig. 3 Location of the Entorhinal Cortex and
Hippocampus in the brain (5)

brain are damaged, causing a detrimental effect on the individual’s activities of daily living
(ADLs) (5). Although this is the process of Alzheimer’s Disease, other forms of dementia also
similarly affect an individual.
There are two forms of AD: early-onset and late-onset. Late-onset Alzheimer’s Disease is
considered sporadic, and the apolipoprotein E gene (APOE) is seen to be a genetic risk factor,
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specifically the 𝜀𝜀4 allele of the APOE gene (14,15). The function of APOE is to regulate the
amount of cholesterol present (15). Individuals with this allele tend to have amyloid-𝛽𝛽 onset
earlier than those that do not carry the allele (15).

4

Generally,

the greatest risk for an individual having Alzheimer’s

Disease is their age (4). The one exception to the rule is thousands of
individuals living with early-onset Alzheimer’s Disease (4). In early-onset
Alzheimer’s Disease, there are two subtypes: common and genetic (familial)
5

(16). The common type of early-onset AD is very similar in progression to
that of late-onset AD, but it forms in adults before the age of 65 (16). The
genetic (familial) type of early-onset Alzheimer’s Disease is rare, as only a
few hundred individuals have this subtype, where a specific gene contributes
to their disease (16). The specific gene mutations that are linked to early-
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onset AD are Amyloid precursor protein (APP), Presenilin 1 (PSEN1), and

Fig. 4 Pathogenic events that lead to
Alzheimer's Disease (17)

Presenilin 2 (PSEN2) (16). The pathogenic events that lead to Alzheimer’s Disease can be seen
in Fig 4. On average, individuals will begin showing symptoms between 30-50 years old (16).
The risk for both subtypes of early-onset Alzheimer’s Disease is a family history (16).

5

Symptoms Of Alzheimer’s Disease
The signs and symptoms of AD vary based on what stage of the disease the individual is
in. A breakdown of the stages of AD can be seen in later sections of this article, however, there
are common signs and symptoms that someone with AD may present with. Beginning with
5

noncognitive symptoms, an individual may present with apathy, depression, agitation,
aggression, and psychosis (1). The cognitive symptoms of Alzheimer’s Disease include problems
with language, memory, and thinking (1). In the early stages of the disease, individuals may have
difficulties remembering the latest conversations, names of family/friends, and important events,
in addition to apathy and depression (1). In the later stages of the disease, individuals may
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include compromised communication, disorientation, confusion, lack of judgment, changes in
behaviors, and difficulty with swallowing, speaking, and walking (1). When symptoms of AD
begin, seeing a practitioner is vital so that a diagnosis can be made.

6

Diagnosis Of Alzheimer’s Disease
Diagnosing Alzheimer’s Disease varies greatly and is dependent on which stage of the
disease the patient currently resides in (10). Individuals on average, live four to eight years
following diagnosis (24).
5

If the patient is in the early stages of the disease, neuropsychological testing, and a MiniMental State Examination (MMSE) can help obtain a baseline for testing in the future (10).
Checking the thyroid and vitamin B-12 levels are important to identify any secondary causes of
dementia and other disorders that are common in the elderly (10). To exclude other forms of
dementia, a CT scan and MRI are obtained (10). The most common way to diagnose a patient
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with Alzheimer’s Disease is through neuropathology and the finding of Amyloid- 𝛽𝛽 plaques or
neurofibrillary tangles (10).

A Mini-Mental State Examination is a commonly used test of cognitive function among

the geriatric population (18). During this assessment, orientation, attention, memory, language,
and visual-spatial skills are examined (18). The MMSE’s scores range from 0-30 (18). If an
15

individual scores above 26, they are deemed competent, scoring from 19-24 indicates the earlier
stages of AD, 10-20 indicates the moderate stage of AD, and scores 9 or less indicate severe AD
(19). Table 1 indicates the scores and matching educational levels (18).
Score
22 or below
24 or below
25 or below
26 or below

Table 1: MMSE scores and corresponding educational levels (18)
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Educational Levels
7th grade or lower
8th grade or some high school
High school graduate
Some college or high school

Treatments
Current treatments for Alzheimer’s
Disease are donepezil, rivastigmine, galantamine,
and memantine and are laid out in Fig 5 (16,10).
5

These medications work to provide individuals
with comfort, dignity, and independence for a
longer time (20). The problem with these
medications is that the disease is not being
modified, rather it is being slowed (20). In 2021,

10

Aducanumab was added to the current treatments
for Alzheimer’s Disease as a disease-modifying

Fig. 5 Current Treatments for Alzheimer's Disease (10)

biologic treatment (20). The purpose of this review is to look at three other medications that are
in the stage-three process of clinical trials for disease-modifying biologics: gantenerumab,
lecanemab, and Solanezumab.
15

Clinical trials for Alzheimer’s disease test and monitor activities of daily living (ADLs),
along with other mental examinations, such as a Mini-Mental State Examination determine the
effectiveness of a specific drug. Activities of daily living are those skills required to manage
one’s basic physical needs, including personal hygiene or grooming, dressing, toileting,
transferring or ambulating, and eating (21). While progressing through the stages of Alzheimer’s
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Disease and other forms of dementia discussed above, individuals will lose the ability to perform
these tasks independently.

8

History Of Alzheimer’s Disease

Fig. 6 The Timeline of the History of Alzheimer’s Disease (16,22,6)

Alois Alzheimer was born (1864) and raised in Marktbreit, Germany (22). Alois attended
5

university in Berlin, Freiburg, and Würzburg where his interest in anatomy and microscopes
developed (22). He obtained his degree in medicine from Würzburg with his dissertation focused
on anatomy (22). In 1852, Alois applied and accepted a position at the “Community Hospital for
Mental and Epileptic Patients in Frankfurt” as a clinical psychiatrist and neuroanatomist (22).
In 1906, Dr. Alois Alzheimer discovered “a peculiar severe disease process of the
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cerebral cortex” (22). This discovery came after the death of his patient, a 50-year-old woman,
Auguste D, whom he first met in 1901 (22). Beginning with her admission to the Frankfurt
Psychiatric Hospital on November 25, 1901 (6), her husband commented on a starting symptom
of paranoia, which then aggressively progressed into “sleep disorders, disturbances of memory,
aggressiveness, crying and progressive confusion” over the next few years until she died in 1906

15

(22). Proceeding her death and autopsy, Dr. Alzheimer examined Mrs. Auguste’s brain at the
cellular and tissue level (16). His findings included changes in the brain that included plaques
9

and “neurofibrillary tangles” (22). With these conclusions, Dr. Alzheimer presented the case and
findings at the “37th Meeting of South-West German Psychiatrists in Tubingen,” however there
were little to no comments or discussion on the topic (22). Following the meeting, the Tubingen
press published and commented on the lectures, however, Dr. Alzheimer’s lecture was only
5

discussed for two lines out of the entire publication (22). This small, yet essential publication
began the research and communication on Alzheimer’s Disease (22).
Following Mrs. Auguste’s case, Dr. Alzheimer published three other cases in 1909 (22).
In 1910, Alzheimer’s Disease was mentioned in the third edition of the textbook Psychiatrié (22).
A year later, Dr. Alzheimer published a “plaque-only variant” where there was no presence of
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neurofibrillary tangles in Mr. Josef F (22). The difference between the “plaque-only variant” and
the presence of both plaque and neurofibrillary tangles was discovered by H-J. Moller and M.B.
Graeber as different stages of Alzheimer’s Disease (22).
Only a few years later, in 1915 and at age 51 (22), Dr. Alois Alzheimer died following
“renal and respiratory failure” (23).

15
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Stages Of Alzheimer’s Disease (24)
Preclinical Stage
At the preclinical stage of Alzheimer’s Disease, the individual is not showing any
symptoms of the disease, however, their brain is undergoing significant changes (25). Due to not
5

showing symptoms and being high-functional (functioning mentally and physically at a higher
level than others with AD (26), individuals are usually not diagnosed in this stage (24).
Mild Stage
Presumably due to aging, individuals at this stage are thought to have mild forgetfulness,
but this forgetfulness is thought to come with aging (25). Additionally, they may have problems
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concentrating on certain tasks, remembering names, recent events, where they put a valuable
object, finding correct words to express themselves, plans they made, how to stay organized,
managing their money, etc. (25,24). Despite these difficulties, the individual still may work,
drive, and participate in social gatherings (27). Due to continuous participation, they may be
aware of their memory problems, as well as their friends and family (25). This worry may

15

warrant an exam from a practitioner, who will be able to identify the symptoms and diagnose
using specific diagnostic tools (27). Once diagnosed, this is the optimal time to make financial,
legal, and end-of-life plans as the individual can participate in these important decisions (27).
Moderate Stage
The moderate stage of Alzheimer’s is on average the longest stage, as it may last for
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several years (27). Patients at this stage have an increasingly more difficult time remembering
events, learning new things, planning complex events, and their names, reading, writing, and
working with numbers (25). As the disease is progressing, the individual may find difficulty in
recognizing family/friends, lose track of time, repeat stories/thoughts/events, and need assistance

11

with activities of daily living. (25,24). Behavioral changes include moodiness, personality
changes, hallucinations, paranoia, delusions, restlessness, agitation, anxiety, and becoming
emotional (25). During this time, it is important to find the activities that the individual can still
complete independently, those that require simplifying, and finally those activities where
5

assistance is needed (27). A concern in this stage of the disease is wandering from home (23). As
the individual progresses through this stage, they may need to transition to a higher level of care
(27).
Moderately Severe Stage
During the moderately severe stage, individuals have significant confusion, as seen with
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not recognizing immediate family members, or thinking that strangers are family members (24).
Additionally, they will continue to decline in the ability to perform activities of daily living, and
urinary and fecal incontinence begin to occur (24). Finally, the individual has sleep disturbance
(24).
Severe Stage
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Those in the severe stage begin a decline in health (24). The individual’s memory is lost,
they need assistance with all ADLs, are unaware of their surroundings, have weight loss, begin
declining in their ability to sit, walk, or eat without aid, and have continued problems with
incontinence (24).
Very Severe Stage

20

In the very late stage of the disease, the individual loses the ability to respond to their
environment, carry on a conversation, and control movement (27). Conversations are scarce as
the individual is only able to say some words and phrases and cannot carry on a conversation
(25), this also leads to difficulty in communicating their pain (27). Although interaction and
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communication are severely limited in this stage, simple things such as listening to relaxing
music, and having gentle care and touch can benefit them (27). A great benefit for individuals
suffering from Alzheimer’s at the end of their life is hospice care (27). Hospice care functions by
providing comfort for the individual, while also keeping their dignity (27) during the last six
5

months or less of their life.
End of Life
During the final stage of Alzheimer’s Disease, individuals forget how to swallow (24).
This significant problem may cause food/drink to enter the trachea and into the lungs rather than
the esophagus to the stomach (24). When food/drink enters the lungs, it may cause infections that
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the individual is unable to combat (24). Other causes of death to an individual with Alzheimer’s
Disease are pneumonia, malnutrition, and dehydration (24).
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Stage 3 Disease-Modifying Biologic Drugs
Gantenerumab
Gantenerumab is a human anti-amyloid-𝛽𝛽 IgG2 monoclonal antibody (28). It
works by binding to Amyloid-𝛽𝛽 aggregates such as oligomers, fibrils, and plaques in the brain
5

(28). Gantenerumab is specifically targeted for individuals in the preclinical and mild stages of
early-onset Alzheimer’s Disease (28). Amyloid plaques are removed by Fc receptor-mediated
phagocytosis (28). The current dosage of gantenerumab is 1200 mg/mo. via subcutaneous
injection to reduce amyloid plaques (28). There are currently seven clinical trials for
gantenerumab, six of which are in stage three trials and can be seen in Table 2.
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There were four, phase one trials for
gantenerumab to determine the safety, tolerability,
pharmacokinetics, and pharmacodynamics of
Gantenerumab (30). The enrollment for these studies
was 308 individuals (30,29). In one of the studies,

15

individuals were randomly placed in one of three
groups: 60 mg gantenerumab, 200 mg gantenerumab,
or placebo (29). The results of this study showed that
the level of cortical brain amyloid decreased by 15.6%

Fig. 6 Median percent change of amyloid load from
baseline of brain areas after treated with placebo, 60
mg of Gantenerumab, and 200 mg of Gantenerumab
(29).

for those in the 60 mg group and 35.7% for those in the 200 mg group (29). As seen in Fig. 7, the
20

amount of amyloid load increases in most parts of the brain in those that were in the placebo
group except for the pons, which originally has only a small amount of amyloid deposition (29).
With those who were in the 60 mg of gantenerumab, on average, the anterior cingular cortex,
medial temporal cortex, and striatum decreased in amyloid deposition, while the other parts of
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the brain still had an increase in deposition (29). In contrast to the individuals in the placebo and
60 mg of gantenerumab groups, in the 200 mg gantenerumab group, each part of the brain
decreased in amyloid load significantly (29). Overall, Fig. 7 indicates that the individuals in the
200 mg gantenerumab group had the most decrease in amyloid load than the placebo or the 60
5

mg gantenerumab group.
In the phase two trial, known as the SCarlet RoAD trial, the researchers determined the
efficacy and safety of gantenerumab in 797 individuals (30,31). Patients were put into one of
three groups: 105 mg
gantenerumab, 225 mg
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gantenerumab, or placebo for two
years (31). In December of 2014,
the trial was discontinued and
unblinded due to futility, however,
the results obtained suggested that

15

Fig. 7 Amount of amyloid-𝛽𝛽 shown in MRIs of five patients at baseline, week
52, and week 104. (32)

dosing at higher amounts would be needed (31).
Following the suggested dose increase of gantenerumab, researchers began a substudy in
which 89 patients were placed into a titration group that had a target goal of 1200 mg every four
weeks (32). The results of this study were that at the year one check-up, 37% of patients had
amyloid-𝛽𝛽 plaques below the baseline, and in year two, the number increased to 51% (32). Fig. 8
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demonstrates the decrease in amyloid- 𝛽𝛽 plaques at year one (52 weeks) and year two (104

weeks) with PET scan axial images of the brain (32). In conclusion, dosing gantenerumab at
1200 mg for two years gave a strong removal of amyloid-𝛽𝛽 plaques (32).
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In Table 2 below, current studies of gantenerumab are presented with the start/end dates,
active/recruiting stage, the number of participants, and the primary outcomes (8).
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Study

Date
Started/

Stage

Participants
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Primary Outcome(s)

“Safety and Efficacy Study
of Gantenerumab in
Participants with Early
Alzheimer’s Disease” (33)

“A Study to Evaluate the
Safety and Tolerability of
Long-term Administration of
Gantenerumab in
Participants with
Alzheimer’s Disease” (34)

“Efficacy and Safety Study
of Gantenerumab in
Participants with Early
Alzheimer’s Disease” (35)

Projected
End date
August
22,
2018
November
23, 2023
May 22,
2020

Active

982

Change from baseline to the 116th week in CDR-GS

Active

116

Recruiting

1016

Percentage of participants with adverse and serious
adverse events, changes in score of Columbia-Suicide
Severity Rating Scale (C-SSRS), participants with
Amyloid-Related Imaging Abnormalities-Edema
(ARIA-E), participants with Amyloid-Related Imaging
Abnormalities-Hemosiderin deposition (ARIA-H),
participants with anti-drug antibody (ADA) to
Gantenerumab, participants with injection-site
reactions, and participants who discontinued treatment
Change from baseline to 116th week in CDR-GS

April 27,
2023

June 6,
2018
November
2,
2023
June 24,
2022

“A Study to Evaluate the
Recruiting
1200
Efficacy and Safety of
Gantenerumab in
Participants at Risk for or at
October
the Earliest Stages of
13,
Alzheimer’s Disease (AD)”
2028
(36)
“A Study to Evaluate the
February
Recruiting
2032
Safety, Tolerability, and
1,
Efficacy of Long-term
2021
Gantenerumab
Administration in
December
Participants with
27,
Alzheimer’s Disease” (37)
2024
“Dominantly Inherited
December, Recruiting
490
Alzheimer Network Trial:
2012
An Opportunity to Prevent
Dementia. A Study of
July,
Potential Disease-Modifying 2022
Treatments in Individuals at
Risk for or With a Type of
Early Onset Alzheimer's
Disease Caused by a Genetic
Mutation. Master Protocol
DIAN-TU001” (38)
Table 2 Gantenerumab: Stage 3, active or recruiting clinical trials (39).
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Change in Preclinical Alzheimer’s Cognitive
Composite-t (PACC-5) scores from baseline to year
four.

Percentage of participants with adverse and serious
adverse events, change in C-SSRS, participants with
ARIA-E, participants with ARIA-H, and participants
with injection-site reactions

Assess cognitive efficacy in individuals whose AD is
caused by mutations measured via the DIANMultivariate Cognitive Endpoint from a change in
baseline to weeks 52, 104, 156, and 208.

Lecanemab
Lecanemab is an IgG1 monoclonal antibody that targets and binds to soluble aggregated
amyloid-𝛽𝛽, specifically oligomers and protofibrils (40). This drug was first developed at
5

BioArctic Neuroscience, where they discovered a mutation in the Amyloid Precursor Protein
(APP) (41). Individuals with the mutation and Alzheimer’s Disease, have high levels of amyloid𝛽𝛽 protofibrils and an absence of amyloid plaques (41). There are currently four clinical trials for
lecanemab, three of which are in stage three trials: AHEAD 3-45, Clarity AD, and DIAN-TU
(42).
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The phase one trial’s purpose was to determine the safety and tolerability of lecanemab or
BAN2401 in 80 subjects with mild-moderate Alzheimer’s Disease (43,41). Its methods included
varying dosages from 0.1 mg/kg each dose to 10 mg/kg biweekly (43). During this trial, they
evaluated Amyloid Related Imaging Abnormalities ((ARIA) E (edema) /H (hemorrhage)) using
magnetic resonance imaging (MRI), and the effects on biomarkers by analyzing their
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Cerebrospinal Fluid (CSF) (43). The results from this trial indicated that the prevalence of
ARIA-E/H was no more common than they were in the placebo, the half-life of lecanemab is
about seven days, and there were no effects of lecanemab on CSF biomarkers (43). The
limitation of this clinical trial was that they could not indicate the most effective dose, because
there were no effects on the CSF biomarkers (43). With these specific findings, they moved on to

20

the efficacy of lecanemab in the phase 2b trial (43).
Following the phase one trial, researchers designed a Bayesian adaptive phase 2, proofof-concept trial (44). The purpose of this trial was to assess the most effective dosage for
BAN2401 in individuals with early AD at ≥90% of effect (44). Based on results from the phase
18

one trial, dosages 5 mg/kg and 10 mg/kg monthly, and 2.5 mg/kg, 5 mg/kg, and 10 mg/kg
biweekly were used (44). A simulation of the study was utilized for 800 subjects (44).
In the phase 2b proof-of-concept clinical trial, researchers hypothesized that reducing
Amyloid-𝛽𝛽 aggregates would be an effective way to treat the early stages of Alzheimer’s Disease
5

(8). The enrollment for this study was 854 individuals (8). This trial, although it did not meet its
original goal of 12-months, as the 10 mg/kg dose showed to be 64% better than the placebo,
rather than the target of 80% (8). Additionally, the tolerability of Lecanemab was assessed and
there was a 9.9% incidence of ARIA-E/H (8). Overall, at 18-months, analyses showed a
reduction in Amyloid-𝛽𝛽, while also reducing the clinical decline in various endpoints (8).
Following this phase 2b clinical trial, are the phase 3 Clarity AD, AHEAD 3-45, and
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DIAN-TU trials as seen in Table 3 (45).
Study

Date
Started/
Projected
End date
July 13,
2020

Stage

Participants

“AHEAD 3-45 Study: A Study
Recruiting
1400
to Evaluate Efficacy and Safety
of Treatment With Lecanemab
in Participants With Preclinical
October
Alzheimer’s Disease and
25,
Elevated Amyloid and Also in
2027
Participants With Early
Preclinical Alzheimer’s Disease
and Intermediate Amyloid”
(46)
“A Study to Confirm Safety and March 27, Active
1766 (set)
Efficacy of Lecanemab in
2019
Participants With Early
Alzheimer’s Disease (Clarity
August
AD)”
29,
(47)
2024
Dominantly Inherited Alzheimer December Recruiting
168
Network Trial: An Opportunity
22, 2021
to Prevent Dementia. A Study of
October,
Potential Disease-Modifying
2027
Treatments in Individuals With
a Type of Early Onset
Alzheimer’s Disease Caused by
a Genetic Mutation (DIANTU)”
(48)
Table 3 Lecanemab: Stage 3, active or recruiting clinical trials (45)
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Primary Outcome(s)

A45 – change from baseline in PACC5
(Preclinical Alzheimer Cognitive
Composite 5) score at 216 weeks
A3 – change from baseline in Amyloid
Positron Emission Tomography (PET)
Standard Uptake Value Ratio (SUVr)
at 216 weeks

Baseline change in the CDR-SB at 18
months

Week 24-104 and week 24-208 in tau
PET in the population with symptoms

Solanezumab
Solanezumab is also a humanized form of immunoglobulin G1 monoclonal antibody that
works by binding to the mid-domain of the amyloid-𝛽𝛽 peptide (7). This antibody is designed to
promote increased clearance of amyloid-𝛽𝛽 peptides (7). Specifically, Solanezumab works by
5

removing soluble Amyloid-𝛽𝛽 that is toxic to neuronal synapse function (49).
The purpose of the phase one trial was to assess the pharmacodynamics,
pharmacokinetics, safety, and tolerability of Solanezumab between white and Japanese
individuals with AD (50). The individuals were divided into two groups: white and Japanese,
then further divided and given via intravenous infusion either 0.5 mg/kg, 1.5 mg/kg, 4.0 mg/kg,

10

or 10.0 mg/kg of Solanezumab (50). Additionally, a study was done in Japan where 400mg of
Solanezumab was given to 33 individuals with mild-moderate AD, and the time intervals were
varied between one, four, or eight weeks (49). Biomarkers studies found specific changes in
“plasma and CSF A𝛽𝛽40, A𝛽𝛽42, plasma pyro-Glu A𝛽𝛽, and plasma and CSF N-terminally
truncated A𝛽𝛽, but not CSF total tau and phosphorylated tau” (49).

15

In the phase two trial, the purpose was to assess Solanezumab’s safety and tolerability
(49). The enrollment for this trial was 52 patients, and they were divided into two groups
(Placebo and Solanezumab), then further subdivided into four groups: 100mg every 4 weeks,
100mg once weekly, 400 mg every 4 weeks, and 400 mg once weekly (51). Those in the
Solanezumab group received the drug for 12 weeks (51). To determine the effectiveness of

20

Solanezumab, researchers used magnetic resonance imaging and CSF (51). For patients in the
group taking 400 mg once weekly, Solanezumab decreased the amount of unbound A𝛽𝛽(1-40) in
CSF, however, the treatment increased the amount of unbound A𝛽𝛽(1-42) in CSF (51). In
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conclusion, researchers believe that Solanezumab may be able to mobilize A𝛽𝛽(1-42) from
plaques of amyloid-𝛽𝛽 (51).
EXPEDITION 1 and EXPEDITION 2 led researchers into phase 3 trials (52). The
purpose of these studies was to see changes from baseline to the 80th week on the Alzheimer’s
5

Disease Assessment Scale, specifically the 11-item cognitive subscale (ADAS-cog11) and the
Alzheimer’s Disease Cooperative Study, the Activities of Daily Living scale (ADCS-ADL) (52).
In EXPEDITION 1, 1012 patients were enrolled, and in EXPEDITION 2 1040 patients were
enrolled (52). In each study, patients were randomly assigned into two groups: placebo or
Solanezumab (52). Those in the Solanezumab group received the dose at 400mg intravenously

10

every 4 weeks for 18 months (52). The results in EXPEDITION 1 showed -0.8 points on the
ADAS-cog11, and -0.4 points on the ADCS-ADL score as seen in Table 4 (52). Following
EXPEDITION 1, EXPEDITION 2, showed -1.3 points on the ADAS-cog11, and +1.6 points on
the ADCS-ADL as seen in Table 5 (52). As seen in the primary outcomes of EXPEDITION 1
and EXPEDITION 2, no study showed noteworthy progress (52).
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Table 4 EXPEDITION 1: Primary and Secondary Outcomes (52)
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Table 5 EXPEDITION 2: Primary and Secondary Outcomes (52).

The third phase three trial, EXPEDITION 3, was completed due to the first two, phase
three trials being unsuccessful (7). The trial design for EXPEDITION 3 explicitly stated that the
5

patients with AD must have evidence via biomarker of an amyloid-related disease through a
positron-emission tomography (PET) scan or cerebrospinal fluid (CSF) (7). The enrollment of
the EXPEDITION 3 study was 2129 individuals with AD, 1057 individuals received the
Solanezumab treatment, and 1072 received the placebo (53). Solanezumab was administered for
76 weeks via intravenous infusion at 400mg or the placebo every four weeks (7). To determine

10

the effectiveness of Solanezumab, they assessed based on the ADAS-cog14, a similar scale to
that of ADAS-cog11 used in the EXPEDITION 1 and EXPEDITION 2 trials (7). The results
from the primary outcome as seen in Table 6 showed the mean change at 80 weeks was +6.65,
whereas the placebo change at 80 weeks was +7.55 (7). The differences in the primary and
secondary outcomes indicated overall that Solanezumab did not significantly reduce cognitive

15

decline (7).
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Table 6 EXPEDITION 3 Primary Outcomes (53)

There are currently two clinical trials for Solanezumab, DIAN-TU, and A4 as seen in
Table 7. DIAN-TU (Dominantly Inherited Alzheimer Network Trial) is a study of potential
5

treatments for individuals who are at risk or have early-onset Alzheimer’s Disease that is caused
by a genetic mutation (53). Particularly, assessing the safety, tolerability, biomarkers, and
cognitive efficacy of Solanezumab (53). This drug will be administered intravenous infusion at
increasing doses every four weeks (53). Alternatively, the purpose of A4 (Clinical Trial for
Solanezumab for Older individuals who may be at risk for Memory Loss) is to test whether

10

Solanezumab can slow the progression of memory difficulties that are associated with amyloid-𝛽𝛽
plaques (54). This drug will be administered through an intravenous infusion at 400-1600mg
every four weeks for 240 weeks (54).

15
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Study

“Dominantly Inherited Alzheimer
Network Trial: An Opportunity to
Prevent Dementia. A Study of
Potential Disease-Modifying
Treatments in Individuals at Risk
for or With a Type of Early Onset
Alzheimer's Disease Caused by a
Genetic Mutation. Master Protocol
DIAN-TU001” (53)
“Clinical Trial of Solanezumab for
Older Individuals Who May Be at
Risk for Memory Loss (A4)” (54)

Date
Started/
Projected
End date
December,
2012

Stage

Participants

Primary Outcome(s)

Recruiting

490

“Assess cognitive efficacy in
individuals with mutations causing
dominantly inherited AD as measured
by the change from baseline in the
DIAN-Multivariate Cognitive
Endpoint”

Active

1150

“Change from baseline of the
Preclinical Alzheimer Cognitive
Composite (PACC)”

July,
2022

February
28,
2014

June 30,
2022
Table 7 Solanezumab: Stage 3, active or recruiting clinical trials (55)
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Conclusion
Dr. Alois Alzheimer, a German neuroanatomist and clinician discovered Amyloid-𝛽𝛽 plaques and
neurofibrillary tangles following the death of Auguste D in 1906. Following this discovery and
research in years to follow, Alzheimer’s Disease was founded as a degenerative brain disease
5

caused by cell damage. Alzheimer’s Disease currently affects six million Americans, and it is
expected to increase to 13 million by 2050. The stages of AD vary based on the resource,
however, this paper focused on six stages: preclinical, mild, moderate, moderately severe, severe,
and very severe with the longest stage being moderate. As the progression through each stage
increases, the independence of performing an individual’s activities of daily living decreases.

10

The effects of AD on the brain and activities of daily living are known, however treating AD is
another story. The current treatments for AD are only used to slow the progression and treat the
symptoms rather than change the disease state. Aducanumab, the first disease-modifying
biologic drug was approved for use in 2021. Three drugs, gantenerumab, lecanemab, and
Solanezumab are also disease-modifying biologics and are currently in stage-three clinical trials.

15

Ganterumab showed promising results in phases one and two, and currently has six, phase three
trials in progress. Lecanemab did not show promising results in its phase one trial, as researchers
could not determine the most effective dosing. The phase two trial, however, showed a reduction
in Amyloid-𝛽𝛽 while also reducing the decline in several clinical endpoints. Lecanemab currently
has three, phase three trials in progress. Solanezumab in both phase one and multiple phase two

20

trials did not show promising results, however, they continue researching as there are two, stage
three trials in progress. In conclusion, the research for Alzheimer’s Disease has a promising
outlook, especially with the disease-modifying biologic drugs currently in clinical trials.
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